Novo is threatening litigation in response to the move by the telehealth company to “unlawfully mass-market” what it called an “unapproved, inauthentic, and untested knockoff” of its fast-selling medication.
Novo is threatening litigation in response to the move by the telehealth company to “unlawfully mass-market” what it called an “unapproved, inauthentic, and untested knockoff” of its fast-selling medication.
